These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 19909752

  • 21. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B.
    Hepatology; 2006 May; 43(5):954-60. PubMed ID: 16628671
    [Abstract] [Full Text] [Related]

  • 22. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS.
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [Abstract] [Full Text] [Related]

  • 23. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
    Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K, Austrian Hepatitis Study Group.
    Hepatology; 2008 Jun; 47(6):1816-23. PubMed ID: 18454510
    [Abstract] [Full Text] [Related]

  • 24. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team.
    N Engl J Med; 2010 Apr 08; 362(14):1292-303. PubMed ID: 20375406
    [Abstract] [Full Text] [Related]

  • 25. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.
    Liver Transpl; 2008 Jan 08; 14(1):53-8. PubMed ID: 18161839
    [Abstract] [Full Text] [Related]

  • 26. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.
    N Engl J Med; 2002 Sep 26; 347(13):975-82. PubMed ID: 12324553
    [Abstract] [Full Text] [Related]

  • 27. Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
    Harrison SA, Abdurakhmanov D, Shiffman ML, Bakulin I, Mazur W, Rodriguez-Torres M, Silva GF, Cheinquer H, Messinger D, Connell EV, McKenna M, Tatsch F, Reddy KR, PROGRESS Investigators.
    J Clin Gastroenterol; 2013 Mar 26; 47(3):271-9. PubMed ID: 22951527
    [Abstract] [Full Text] [Related]

  • 28. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
    Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, Wright TL, Fried M.
    Clin Gastroenterol Hepatol; 2007 Jan 26; 5(1):124-9. PubMed ID: 17196435
    [Abstract] [Full Text] [Related]

  • 29. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
    Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P, Kerschner H, Kessler HH, Ferenci P.
    J Hepatol; 2011 May 26; 54(5):866-71. PubMed ID: 21145807
    [Abstract] [Full Text] [Related]

  • 30. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R, Cariti G, Nasta P, Capetti A, Ravasio V, Galli M, Raise E, Palmieri G, Iannacone C, Puoti M.
    Liver Int; 2015 Jan 26; 35(1):120-9. PubMed ID: 25041136
    [Abstract] [Full Text] [Related]

  • 31. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
    Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB.
    Gastroenterology; 2009 Mar 26; 136(3):856-62. PubMed ID: 19135998
    [Abstract] [Full Text] [Related]

  • 32. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
    Mangia A, Bányai T, De Bartolomeo G, Gervain J, Habersetzer F, Mulkay JP, Ouzan D, Parruti G, Passariello N, Remy AJ, Rizzetto M, Shiffman ML, Tice AD, Schmitz M, Tatsch F, Rodriguez-Torres M.
    Liver Int; 2014 Aug 26; 34(7):e217-28. PubMed ID: 24251988
    [Abstract] [Full Text] [Related]

  • 33. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
    Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML.
    Aliment Pharmacol Ther; 2008 Mar 01; 27(5):433-40. PubMed ID: 18081737
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
    Scherzer TM, Stättermayer AF, Strasser M, Laferl H, Maieron A, Stauber R, Datz C, Dulic-Lakovic E, Steindl-Munda P, Hofer H, Ferenci P.
    Hepatology; 2011 Nov 01; 54(5):1518-26. PubMed ID: 22006276
    [Abstract] [Full Text] [Related]

  • 36. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.
    Rev Invest Clin; 2003 Nov 01; 55(2):138-42. PubMed ID: 12827916
    [Abstract] [Full Text] [Related]

  • 37. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 38. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
    Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.
    Clin Infect Dis; 2008 Nov 15; 47(10):1260-9. PubMed ID: 18834319
    [Abstract] [Full Text] [Related]

  • 39. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK.
    J Viral Hepat; 2007 Oct 15; 14(10):721-9. PubMed ID: 17875007
    [Abstract] [Full Text] [Related]

  • 40. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.
    García-Samaniego J, Romero M, Granados R, Alemán R, Jorge Juan M, Suárez D, Pérez R, Castellano G, González-Portela C.
    World J Gastroenterol; 2013 Mar 28; 19(12):1943-52. PubMed ID: 23569340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.